The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.
Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach
Open accessAbstract
The sudden emergence of severe respiratory disease, caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has recently become a public health emergency. Genome sequence analysis of SARS-CoV-2 revealed its close resemblance to the earlier reported SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV). However, initial testing of the drugs used against SARS-CoV and MERS-CoV has been ineffective in controlling SARS-CoV-2. The present study highlights the genomic, proteomic, pathogenesis, and therapeutic strategies in SARS-CoV-2 infection. We have carried out sequence analysis of potential drug target proteins in SARS-CoV-2 and, compared them with SARS-CoV and MERS viruses. Analysis of mutations in the coding and non-coding regions, genetic diversity, and pathogenicity of SARS-CoV-2 has also been done. A detailed structural analysis of drug target proteins has been performed to gain insights into the mechanism of pathogenesis, structure-function relationships, and the development of structure-guided therapeutic approaches. The cytokine profiling and inflammatory signalling are different in the case of SARS-CoV-2 infection. We also highlighted possible therapies and their mechanism of action followed by clinical manifestation. Our analysis suggests a minimal variation in the genome sequence of SARS-CoV-2, may be responsible for a drastic change in the structures of target proteins, which makes available drugs ineffective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia
Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575
Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30251-8 · Cited by 11,907
A new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Pathological findings of COVID-19 associated with acute respiratory distress syndrome
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30076-x · Cited by 8,545
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983
The proximal origin of SARS-CoV-2
Andersen, K. G., Rambaut, A., Lipkin, W. I., Holmes, E. C., & Garry, R. F. (2020) · Nature Medicine · doi:10.1038/s41591-020-0820-9 · Cited by 5,081
Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2
Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., & Zhou, Q. (2020) · Science · doi:10.1126/science.abb2762 · Cited by 5,040
SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients
Zou, L., Ruan, F., Huang, M., Liang, L., Huang, H., Hong, Z., Yu, J., Kang, M., Song, Y., Xia, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2001737 · Cited by 4,810
Coronaviruses: An Overview of Their Replication and Pathogenesis
Fehr, A. R., & Perlman, S. (2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2438-7_1 · Cited by 3,787
Structural basis of receptor recognition by SARS-CoV-2
Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., & Li, F. (2020) · Nature · doi:10.1038/s41586-020-2179-y · Cited by 3,661
Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31022-9 · Cited by 3,440
Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15562-9 · Cited by 3,097
Emerging coronaviruses: Genome structure, replication, and pathogenesis
Chen, Y., Liu, Q., & Guo, D. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25681 · Cited by 3,062
Zhang, L., Lin, D., Sun, X., Curth, U., Drosten, C., Sauerhering, L., Becker, S., Rox, K., & Hilgenfeld, R. (2020) · Science · doi:10.1126/science.abb3405 · Cited by 2,895
High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa
Xu, H., Zhong, L., Deng, J., Peng, J., Dan, H., Zeng, X., Li, T., & Chen, Q. (2020) · International Journal of Oral Science · doi:10.1038/s41368-020-0074-x · Cited by 2,838
Compassionate Use of Remdesivir for Patients with Severe Covid-19
Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., Feldt, T., Green, G., Green, M. L., Lescure, F.-X., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007016 · Cited by 2,737
Zhang, H., Penninger, J. M., Li, Y., Zhong, N., & Slutsky, A. S. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05985-9 · Cited by 2,684
Effective treatment of severe COVID-19 patients with tocilizumab
Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., Zhou, Y., Zheng, X., Yang, Y., Li, X., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005615117 · Cited by 2,647
Gao, J., Tian, Z., & Yang, X. (2020) · BioScience Trends · doi:10.5582/bst.2020.01047 · Cited by 2,590
Bats Are Natural Reservoirs of SARS-Like Coronaviruses
Li, W., Shi, Z., Yu, M., Ren, W., Smith, C., Epstein, J. H., Wang, H., Crameri, G., Hu, Z., Zhang, H., et al. (2005) · Science · doi:10.1126/science.1118391 · Cited by 2,560
Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts
Hellewell, J., Abbott, S., Gimma, A., Bosse, N. I., Jarvis, C. I., Russell, T. W., Munday, J. D., Kucharski, A. J., Edmunds, W. J., Sun, F., et al. (2020) · The Lancet Global Health · doi:10.1016/s2214-109x(20)30074-7 · Cited by 2,550
Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Rota, P. A., Oberste, M. S., Monroe, S. S., Nix, W. A., Campagnoli, R., Icenogle, J. P., Peñaranda, S., Bankamp, B., Maher, K., Chen, M.-H., et al. (2003) · Science · doi:10.1126/science.1085952 · Cited by 2,474
Velavan, T. P., & Meyer, C. G. (2020) · Tropical Medicine & International Health · doi:10.1111/tmi.13383 · Cited by 2,439
Guan, Y., Zheng, B. J., He, Y. Q., Liu, X. L., Zhuang, Z. X., Cheung, C. L., Luo, S. W., Li, P. H., Zhang, L. J., Guan, Y. J., et al. (2003) · Science · doi:10.1126/science.1087139 · Cited by 2,406
Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China
Wu, A., Peng, Y., Huang, B., Ding, X., Wang, X., Niu, P., Meng, J., Zhu, Z., Zhang, Z., Wang, J., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.02.001 · Cited by 2,361
Wu, C., Liu, Y., Yang, Y., Zhang, P., Zhong, W., Wang, Y., Wang, Q., Xu, Y., Li, M., Li, X., et al. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.02.008 · Cited by 2,330
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., Wang, F., Li, D., Yang, M., Xing, L., et al. (2020) · JAMA · doi:10.1001/jama.2020.4783 · Cited by 2,277
Liu, J., Cao, R., Xu, M., Wang, X., Zhang, H., Hu, H., Li, Y., Hu, Z., Zhong, W., & Wang, M. (2020) · Cell Discovery · doi:10.1038/s41421-020-0156-0 · Cited by 2,070
Effectiveness of convalescent plasma therapy in severe COVID-19 patients
Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J., Zhou, M., Chen, L., Meng, S., Hu, Y., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004168117 · Cited by 1,960
Zhang, C., Wu, Z., Li, J.-W., Zhao, H., & Wang, G.-Q. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105954 · Cited by 1,758
Sheahan, T. P., Sims, A. C., Leist, S. R., Schäfer, A., Won, J., Brown, A. J., Montgomery, S. A., Hogg, A., Babusis, D., Clarke, M. O., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13940-6 · Cited by 1,738
Coronavirus Main Proteinase (3CL pro ) Structure: Basis for Design of Anti-SARS Drugs
Anand, K., Ziebuhr, J., Wadhwani, P., Mesters, J. R., & Hilgenfeld, R. (2003) · Science · doi:10.1126/science.1085658 · Cited by 1,728
Coronaviruses — drug discovery and therapeutic options
Zumla, A., Chan, J. F. W., Azhar, E. I., Hui, D. S. C., & Yuen, K.-Y. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.37 · Cited by 1,707
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,661
COVID-19: immunopathology and its implications for therapy
Cao, X. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0308-3 · Cited by 1,609
Structure of the RNA-dependent RNA polymerase from COVID-19 virus
Gao, Y., Yan, L., Huang, Y., Liu, F., Zhao, Y., Cao, L., Wang, T., Sun, Q., Ming, Z., Zhang, L., et al. (2020) · Science · doi:10.1126/science.abb7498 · Cited by 1,609
COVID-19 infection: the perspectives on immune responses
Shi, Y., Wang, Y., Shao, C., Huang, J., Gan, J., Huang, X., Bucci, E., Piacentini, M., Ippolito, G., & Melino, G. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-020-0530-3 · Cited by 1,594
Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats
Lau, S. K. P., Woo, P. C. Y., Li, K. S. M., Huang, Y., Tsoi, H.-W., Wong, B. H. L., Wong, S. S. Y., Leung, S.-Y., Chan, K.-H., & Yuen, K.-Y. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506735102 · Cited by 1,544
Mészáros, B., Erdős, G., & Dosztányi, Z. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky384 · Cited by 1,473
Channappanavar, R., Fehr, A. R., Vijay, R., Mack, M., Zhao, J., Meyerholz, D. K., & Perlman, S. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.01.007 · Cited by 1,419
Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak
Zhang, T., Wu, Q., & Zhang, Z. (2020) · Current Biology · doi:10.1016/j.cub.2020.03.022 · Cited by 1,397
Liu, C., Zhou, Q., Li, Y., Garner, L. V., Watkins, S. P., Carter, L. J., Smoot, J., Gregg, A. C., Daniels, A. D., Jervey, S., et al. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00272 · Cited by 1,297
Zhang, W., Zhao, Y., Zhang, F., Wang, Q., Li, T., Liu, Z., Wang, J., Qin, Y., Zhang, X., Yan, X., et al. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108393 · Cited by 1,266
Tocilizumab treatment in COVID‐19: A single center experience
Luo, P., Liu, Y., Qiu, L., Liu, X., Liu, D., & Li, J. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25801 · Cited by 1,237
Snijder, E. J., Bredenbeek, P. J., Dobbe, J. C., Thiel, V., Ziebuhr, J., Poon, L. L. M., Guan, Y., Rozanov, M., Spaan, W. J. M., & Gorbalenya, A. E. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(03)00865-9 · Cited by 1,198
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19
Cortegiani, A., Ingoglia, G., Ippolito, M., Giarratano, A., & Einav, S. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.03.005 · Cited by 1,160
Leng, Z., Zhu, R., Hou, W., Feng, Y., Yang, Y., Han, Q., Shan, G., Meng, F., Du, D., Wang, S., et al. (2020) · Aging and disease · doi:10.14336/ad.2020.0228 · Cited by 1,147
Zhang, P., Zhu, L., Cai, J., Lei, F., Qin, J.-J., Xie, J., Liu, Y.-M., Zhao, Y.-C., Huang, X., Lin, L., et al. (2020) · Circulation Research · doi:10.1161/circresaha.120.317134 · Cited by 1,133
Convalescent plasma as a potential therapy for COVID-19
Chen, L., Xiong, J., Bao, L., & Shi, Y. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30141-9 · Cited by 1,038
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
Colson, P., Rolain, J.-M., Lagier, J.-C., Brouqui, P., & Raoult, D. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105932 · Cited by 937
Elfiky, A. A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117592 · Cited by 923
Chan, J. F.-W., Yip, C. C.-Y., To, K. K.-W., Tang, T. H.-C., Wong, S. C.-Y., Leung, K.-H., Fung, A. Y.-F., Ng, A. C.-K., Zou, Z., Tsoi, H.-W., et al. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.00310-20 · Cited by 880
A Genomic Perspective on the Origin and Emergence of SARS-CoV-2
Zhang, Y.-Z., & Holmes, E. C. (2020) · Cell · doi:10.1016/j.cell.2020.03.035 · Cited by 818
Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics
Gurwitz, D. (2020) · Drug Development Research · doi:10.1002/ddr.21656 · Cited by 802
TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib
Wu, D., & Yang, X. O. (2020) · Journal of Microbiology, Immunology and Infection · doi:10.1016/j.jmii.2020.03.005 · Cited by 785
Morse, J. S., Lalonde, T., Xu, S., & Liu, W. R. (2020) · ChemBioChem · doi:10.1002/cbic.202000047 · Cited by 776
COVID-19, ACE2, and the cardiovascular consequences
South, A. M., Diz, D. I., & Chappell, M. C. (2020) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00217.2020 · Cited by 762
Coronavirus membrane fusion mechanism offers a potential target for antiviral development
Tang, T., Bidon, M., Jaimes, J. A., Whittaker, G. R., & Daniel, S. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104792 · Cited by 761
Infection of dogs with SARS-CoV-2
Sit, T. H. C., Brackman, C. J., Ip, S. M., Tam, K. W. S., Law, P. Y. T., To, E. M. W., Yu, V. Y. T., Sims, L. D., Tsang, D. N. C., Chu, D. K. W., et al. (2020) · Nature · doi:10.1038/s41586-020-2334-5 · Cited by 744
Anti-HCV, nucleotide inhibitors, repurposing against COVID-19
Elfiky, A. A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117477 · Cited by 715
Xu, J., Zhao, S., Teng, T., Abdalla, A. E., Zhu, W., Xie, L., Wang, Y., & Guo, X. (2020) · Viruses · doi:10.3390/v12020244 · Cited by 683
Runfeng, L., Yunlong, H., Jicheng, H., Weiqi, P., Qinhai, M., Yongxia, S., Chufang, L., Jin, Z., Zhenhua, J., Haiming, J., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104761 · Cited by 660
Anand, K. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf327 · Cited by 618
Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion
Walls, A. C., Xiong, X., Park, Y.-J., Tortorici, M. A., Snijder, J., Quispe, J., Cameroni, E., Gopal, R., Dai, M., Lanzavecchia, A., et al. (2019) · Cell · doi:10.1016/j.cell.2018.12.028 · Cited by 582
Haga, S., Yamamoto, N., Nakai-Murakami, C., Osawa, Y., Tokunaga, K., Sata, T., Yamamoto, N., Sasazuki, T., & Ishizaka, Y. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711241105 · Cited by 521
Ton, A., Gentile, F., Hsing, M., Ban, F., & Cherkasov, A. (2020) · Molecular Informatics · doi:10.1002/minf.202000028 · Cited by 517
The SARS-CoV-2 Vaccine Pipeline: an Overview
Chen, W.-H., Strych, U., Hotez, P. J., & Bottazzi, M. E. (2020) · Current Tropical Medicine Reports · doi:10.1007/s40475-020-00201-6 · Cited by 511
A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike
Xia, S., Yan, L., Xu, W., Agrawal, A. S., Algaissi, A., Tseng, C.-T. K., Wang, Q., Du, L., Tan, W., Wilson, I. A., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav4580 · Cited by 501
Immunopathogenesis of coronavirus infections: implications for SARS
Dandekar, A. A., & Perlman, S. (2005) · Nature Reviews Immunology · doi:10.1038/nri1732 · Cited by 499
Malik, Y. S., Sircar, S., Bhat, S., Sharun, K., Dhama, K., Dadar, M., Tiwari, R., & Chaicumpa, W. (2020) · Veterinary Quarterly · doi:10.1080/01652176.2020.1727993 · Cited by 498
Omrani, A. S., Saad, M. M., Baig, K., Bahloul, A., Abdul-Matin, M., Alaidaroos, A. Y., Almakhlafi, G. A., Albarrak, M. M., Memish, Z. A., & Albarrak, A. M. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70920-x · Cited by 493
Chen, J., Lee, K. H., Steinhauer, D. A., Stevens, D. J., Skehel, J. J., & Wiley, D. C. (1998) · Cell · doi:10.1016/s0092-8674(00)81771-7 · Cited by 477
Shi, C.-S., Qi, H.-Y., Boularan, C., Huang, N.-N., Abu-Asab, M., Shelhamer, J. H., & Kehrl, J. H. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1303196 · Cited by 473
COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?
Sarzi-Puttini, P., Giorgi, V., Sirotti, S., Marotto, D., Ardizzone, S., Rizzardini, G., Antinori, S., & Galli, M. (2020) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/xcdary · Cited by 466
Harcourt, B. H., Jukneliene, D., Kanjanahaluethai, A., Bechill, J., Severson, K. M., Smith, C. M., Rota, P. A., & Baker, S. C. (2004) · Journal of Virology · doi:10.1128/jvi.78.24.13600-13612.2004 · Cited by 462
Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak
Zhang, T., Wu, Q., & Zhang, Z. (2020) · Current Biology · doi:10.1016/j.cub.2020.03.063 · Cited by 426
SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon
Totura, A. L., & Baric, R. S. (2012) · Current Opinion in Virology · doi:10.1016/j.coviro.2012.04.004 · Cited by 415
Cong, Y., Ulasli, M., Schepers, H., Mauthe, M., V’kovski, P., Kriegenburg, F., Thiel, V., de Haan, C. A. M., & Reggiori, F. (2020) · Journal of Virology · doi:10.1128/jvi.01925-19 · Cited by 384
Antivirals and antiviral strategies
Clercq, E. D. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro975 · Cited by 370
Mesenchymal Stem Cell Therapy for COVID-19: Present or Future
Golchin, A., Seyedjafari, E., & Ardeshirylajimi, A. (2020) · Stem Cell Reviews and Reports · doi:10.1007/s12015-020-09973-w · Cited by 332
Egloff, M.-P., Ferron, F., Campanacci, V., Longhi, S., Rancurel, C., Dutartre, H., Snijder, E. J., Gorbalenya, A. E., Cambillau, C., & Canard, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307877101 · Cited by 306
Fan, H.-H., Wang, L.-Q., Liu, W.-L., An, X.-P., Liu, Z.-D., He, X.-Q., Song, L.-H., & Tong, Y.-G. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000797 · Cited by 304
Josset, L., Menachery, V. D., Gralinski, L. E., Agnihothram, S., Sova, P., Carter, V. S., Yount, B. L., Graham, R. L., Baric, R. S., & Katze, M. G. (2013) · mBio · doi:10.1128/mbio.00165-13 · Cited by 293
Insights into SARS-CoV transcription and replication from the structure of the nsp7–nsp8 hexadecamer
Zhai, Y., Sun, F., Li, X., Pang, H., Xu, X., Bartlam, M., & Rao, Z. (2005) · Nature Structural & Molecular Biology · doi:10.1038/nsmb999 · Cited by 290
Coronavirus infection, ER stress, apoptosis and innate immunity
Fung, T. S., & Liu, D. X. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00296 · Cited by 278
Drug Repurposing for Viral Infectious Diseases: How Far Are We?
Mercorelli, B., Palù, G., & Loregian, A. (2018) · Trends in Microbiology · doi:10.1016/j.tim.2018.04.004 · Cited by 264
Updated Approaches against SARS-CoV-2
Li, H., Zhou, Y., Zhang, M., Wang, H., Zhao, Q., & Liu, J. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00483-20 · Cited by 258
Treating COVID-19 with Chloroquine
Huang, M., Tang, T., Pang, P., Li, M., Ma, R., Lu, J., Shu, J., You, Y., Chen, B., Liang, J., et al. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa014 · Cited by 251
MERS-CoV papain-like protease has deISGylating and deubiquitinating activities
Mielech, A. M., Kilianski, A., Baez-Santos, Y. M., Mesecar, A. D., & Baker, S. C. (2014) · Virology · doi:10.1016/j.virol.2013.11.040 · Cited by 231
Membrane Binding Proteins of Coronaviruses
J Alsaadi, E. A., & Jones, I. M. (2019) · Future Virology · doi:10.2217/fvl-2018-0144 · Cited by 230
Manchikanti, L. (2020) · Pain Physician · doi:10.36076/ppj.2020/23/e71 · Cited by 227
Robson, B. (2020) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2020.103670 · Cited by 223
Sexton, N. R., Smith, E. C., Blanc, H., Vignuzzi, M., Peersen, O. B., & Denison, M. R. (2016) · Journal of Virology · doi:10.1128/jvi.00080-16 · Cited by 209
Structural Disorder in Viral Proteins
Xue, B., Blocquel, D., Habchi, J., Uversky, A. V., Kurgan, L., Uversky, V. N., & Longhi, S. (2014) · Chemical Reviews · doi:10.1021/cr4005692 · Cited by 202
Müller, C., Schulte, F. W., Lange-Grünweller, K., Obermann, W., Madhugiri, R., Pleschka, S., Ziebuhr, J., Hartmann, R. K., & Grünweller, A. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2017.12.010 · Cited by 200
Neuvonen, M., & Ahola, T. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.10.045 · Cited by 191
Tan, J., Verschueren, K. H. G., Anand, K., Shen, J., Yang, M., Xu, Y., Rao, Z., Bigalke, J., Heisen, B., Mesters, J. R., et al. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.09.012 · Cited by 184
Misguided drug advice for COVID-19
FitzGerald, G. A. (2020) · Science · doi:10.1126/science.abb8034 · Cited by 172
Ma, J., Xia, P., Zhou, Y., Liu, Z., Zhou, X., Wang, J., Li, T., Yan, X., Chen, L., Zhang, S., et al. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108408 · Cited by 171
Pathogenesis of severe acute respiratory syndrome
Lau, Y. L., & Peiris, J. M. (2005) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.05.009 · Cited by 168
Shamsi, A., Mohammad, T., Anwar, S., AlAjmi, M. F., Hussain, A., Rehman, M. T., Islam, A., & Hassan, M. I. (2020) · Bioscience Reports · doi:10.1042/bsr20201256 · Cited by 167
Self-citationJawhara, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072272 · Cited by 163
Interleukin-6 Is a Potential Biomarker for Severe Pandemic H1N1 Influenza A Infection
Paquette, S. G., Banner, D., Zhao, Z., Yuan, F., Huang, S. S. H., Leon, A. J., Ng, D. C. K., Almansa, R., Martín‐Loeches, I., Ramírez, P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038214 · Cited by 160
A reevaluation of the higher taxonomy of viruses based on RNA polymerases
Zanotto, P. M. D. A., Gibbs, M. J., Gould, E. A., & Holmes, E. C. (1996) · Journal of Virology · doi:10.1128/jvi.70.9.6083-6096.1996 · Cited by 160
Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections
Okabayashi, T., Kariwa, H., Yokota, S.-I., Iki, S., Indoh, T., Yokosawa, N., Takashima, I., Tsutsumi, H., & Fujii, N. (2006) · Journal of Medical Virology · doi:10.1002/jmv.20556 · Cited by 158
The potential of mesenchymal stem cell therapy for chronic lung disease
Cruz, F. F., & Rocco, P. R. M. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1679628 · Cited by 155
SARS coronavirus replicase proteins in pathogenesis
Graham, R. L., Sparks, J. S., Eckerle, L. D., Sims, A. M., & Denison, M. R. (2007) · Virus Research · doi:10.1016/j.virusres.2007.02.017 · Cited by 154
Kleine‐Weber, H., Elzayat, M. T., Wang, L., Graham, B. S., Müller, M. A., Drosten, C., Pöhlmann, S., & Hoffmann, M. (2018) · Journal of Virology · doi:10.1128/jvi.01381-18 · Cited by 152
Supramolecular Architecture of the Coronavirus Particle
Neuman, B. W., & Buchmeier, M. J. (2016) · Advances in virus research · doi:10.1016/bs.aivir.2016.08.005 · Cited by 149
Forty years with coronaviruses
Weiss, S. R. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20200537 · Cited by 143
mRNA Cap-1 Methyltransferase in the SARS Genome
von Grotthuss, M., Wyrwicz, L. S., & Rychlewski, L. (2003) · Cell · doi:10.1016/s0092-8674(03)00424-0 · Cited by 140
Almeida, M. S., Johnson, M. A., Herrmann, T., Geralt, M., & Kurt Wüthrich, A. (2007) · Journal of Virology · doi:10.1128/jvi.01939-06 · Cited by 136
Zhang, P., Zhu, L., Cai, J., Lei, F., Qin, J., Wang, Y., Yuan, Y., Loomba, R. S., Liu, P. P., & Li, H. (2020) · Circulation Research · doi:10.1161/circresaha.120.317242 · Cited by 136
Regulation of RIG-I-like receptor signaling by host and viral proteins
Chiang, J. J., Davis-Gardner, M. E., & Gack, M. U. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.06.005 · Cited by 134
Ruan, Z., Liu, C., Guo, Y., He, Z., Huang, X., Jia, X., & Yang, T. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26222 · Cited by 125
Ribavirin in the treatment of SARS: A new trick for an old drug?
Koren, G., King, S., Knowles, S. R., & Phillips, E. W. (2003) · Europe PMC (PubMed Central) · Cited by 124
Joseph, J. S., Saikatendu, K. S., Subramanian, V., Neuman, B. W., Brooun, A., Griffith, M. T., Moy, K., Yadav, M. K., Velasquez, J., Buchmeier, M. J., et al. (2006) · Journal of Virology · doi:10.1128/jvi.00467-06 · Cited by 121
Bhatnagar, T., Murhekar, M. V., Soneja, M., Gupta, N., Giri, S., Wig, N., & Gangakhedkar, R. (2020) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_502_20 · Cited by 111
Deng, X., John, S. E. S., Osswald, H. L., O’Brien, A., Banach, B. S., Sleeman, K., Ghosh, A. K., Mesecar, A. D., & Baker, S. C. (2014) · Journal of Virology · doi:10.1128/jvi.01528-14 · Cited by 100
Suzuki, T., Otake, Y., Uchimoto, S., Hasebe, A., & Goto, Y. (2020) · Viruses · doi:10.3390/v12020183 · Cited by 94
Li, S., Yuan, L., Dai, G., Chen, R., Liu, D. X., & Fung, T. S. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.03022 · Cited by 82
NSAIDs in patients with viral infections, including Covid-19: Victims or perpetrators?
Capuano, A., Scavone, C., Racagni, G., & Scaglione, F. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104849 · Cited by 77
Covid-19: European drugs agency to review safety of ibuprofen
Day, M. J. (2020) · BMJ · doi:10.1136/bmj.m1168 · Cited by 76
Peti, W., Johnson, M. A., Herrmann, T., Neuman, B. W., Buchmeier, M. J., Nelson, M., Joseph, J. S., Page, R., Stevens, R. C., Kühn, P., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.20.12905-12913.2005 · Cited by 68
Coronavirus shuts down trials of drugs for multiple other diseases
Ledford, H. K. (2020) · Nature · doi:10.1038/d41586-020-00889-6 · Cited by 62
Drug Targets in Severe Acute Respiratory Syndrome (SARS) Virus and other Coronavirus Infections
Tong, T. R. S.-W. (2009) · Infectious Disorders - Drug Targets · doi:10.2174/187152609787847659 · Cited by 61
Tilorone: a Broad-Spectrum Antiviral Invented in the USA and Commercialized in Russia and beyond
Ekins, S., Lane, T. R., & Madrid, P. B. (2020) · Pharmaceutical Research · doi:10.1007/s11095-020-02799-8 · Cited by 60
Huang, G., Xu, J., Liu, J., He, Y., Nie, X.-L., Li, Q., Hu, Y., Zhao, S.-Q., Wang, M., Zhang, W., et al. (2011) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02460.x · Cited by 52
Selinger, C., Tisoncik-Go, J., Menachery, V. D., Agnihothram, S., Law, G. L., Chang, J., Kelly, S. M., Sova, P., Baric, R. S., & Katze, M. G. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-1161 · Cited by 51
Qing, E., & Gallagher, T. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.02.007 · Cited by 50
Structure of the C-terminal domain of nsp4 from feline coronavirus
Manolaridis, I., Wojdyla, J. A., Panjikar, S., Snijder, E. J., Gorbalenya, A. E., Berglind, H., Nordlund, P., Coutard, B., & Tucker, P. A. (2009) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909018253 · Cited by 32
Recent human genetic errors of innate immunity leading to increased susceptibility to infection
Moens, L., & Meyts, I. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2019.12.002 · Cited by 26
Tang, C., Deng, Z., Li, X., Yang, M., Tian, Z., Chen, Z., Wang, G., Wu, W., Feng, W.-H., Zhang, G., et al. (2020) · Viruses · doi:10.3390/v12020215 · Cited by 23
Research works printed but not linked: 20
- Lu, 2015, Complete genome sequence of Middle East respiratory syndrome coronavirus (MERS-CoV) from the first imported MERS-CoV case in China, Genome Announc., 3, 10.1128/genomeA.00818-15 · doi:10.1128/genomea.00818-15
- Graham, 2020, SARS-CoV-2: Combating Coronavirus Emergence, Immunity, 52, 734, 10.1016/j.immuni.2020.04.016 · doi:10.1016/j.immuni.2020.04.016
- Nishikiori, 2012, Crystal structure of the superfamily 1 helicase from tomato mosaic virus, J. Virol., 86, 7565, 10.1128/JVI.00118-12 · doi:10.1128/jvi.00118-12
- van Dinten, 2000, The predicted metal-binding region of the arterivirus helicase protein is involved in subgenomic mRNA synthesis, genome replication, and virion biogenesis, J. Virol., 74, 5213, 10.1128/JVI.74.11.5213-5223.2000 · doi:10.1128/jvi.74.11.5213-5223.2000
- Bomma, 2012, PONDR (predicators of natural disorder regions), International Journal of Computer Technology and Electronics Engineering, 21, 61
- Minakshi, 2014, The SARS coronavirus 3a protein binds calcium in its cytoplasmic domain, Virus Res., 191, 180, 10.1016/j.virusres.2014.08.001 · doi:10.1016/j.virusres.2014.08.001
- Wrapp, 2020, Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation, Science, 367, 1260, 10.1126/science.abb2507 · DOI · Paper page
- Hassan, 2016, Editorial. Recent advances in the structure-based drug design and discovery, Curr. Top. Med. Chem., 16, 899, 10.2174/1568026616999150918145640 · doi:10.2174/1568026616999150918145640
- Greene, 2020, Innate immunity of the lung, Journal of Innate Immunity, 12, 1, 10.1159/000504621 · doi:10.1159/000504621
- Guastalegname, 2020, Could chloroquine /hydroxychloroquine be harmful in Coronavirus Disease 2019 (COVID-19) treatment?, Clin. Infect. Dis., ciaa321
- Elfiky, 2020, Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study, Life Sci., 117592
- Zumla, 2016, Coronaviruses—drug discovery and therapeutic options, Nat. Rev. Drug Discov., 15, 327, 10.1038/nrd.2015.37 · DOI · Paper page
- Schlagenhauf, 2020, Repurposing antimalarials and other drugs for COVID-19, Travel Med. Infect. Dis., 34, 101658, 10.1016/j.tmaid.2020.101658 · doi:10.1016/j.tmaid.2020.101658
- Hong, 2020, Combating COVID-19 with chloroquine, J Mol Cell Biol, 12, 249, 10.1093/jmcb/mjaa015 · doi:10.1093/jmcb/mjaa015
- Cao, 2020, COVID-19: immunopathology and its implications for therapy, Nat Rev Immunol, 20, 269, 10.1038/s41577-020-0308-3 · DOI · Paper page
- Duan, 2019, COVID-19 and its research progress in forensic toxicology, Fa Yi Xue Za Zhi, 36
- FitzGerald, 2020, Misguided drug advice for COVID-19, Science, 367, 1434, 10.1126/science.abb8034 · DOI · Paper page
- Orleans, 2020, Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically ill COVID-19 patients: The case for compassionate use, Pain Physician, 23, E71
- Wang, 2005, Study on the resistance of severe acute respiratory syndrome-associated coronavirus, J. Virol. Methods, 126, 171, 10.1016/j.jviromet.2005.02.005 · doi:10.1016/j.jviromet.2005.02.005
- Shamsi, 2020, Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy, Bioscience Reports, 40, 10.1042/BSR20201256 · DOI · Paper page
Cited by
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983
Gao, J., Tian, Z., & Yang, X. (2020) · BioScience Trends · doi:10.5582/bst.2020.01047 · Cited by 2,590
Velavan, T. P., & Meyer, C. G. (2020) · Tropical Medicine & International Health · doi:10.1111/tmi.13383 · Cited by 2,439
SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development
Wang, M.-Y., Zhao, R., Gao, L.-J., Gao, X.-F., Wang, D.-P., & Cao, J.-M. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.587269 · Cited by 874
Runfeng, L., Yunlong, H., Jicheng, H., Weiqi, P., Qinhai, M., Yongxia, S., Chufang, L., Jin, Z., Zhenhua, J., Haiming, J., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104761 · Cited by 660
Metadata
- Authors
- Naqvi, A. A. T., Fatima, K., Mohammad, T., Fatima, U., Singh, I. K., Singh, A., Atif, S. M., Hariprasad, G., Hasan, G. M., & Hassan, M. I.
- Venue
- Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 1866
- Issue
- 10
- Pages
- 165878
- ISSN
- 0925-4439 (ISSN-L)
- OpenAlex
- W3035265089
- Cited by
- 1,114
- References
- 140
- FWCI
- 26.56
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 365 d)
- Funders
- Indian Council of Medical Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.